Jagsonpal Pharmaceuticals Limited — Updates, 06-05-2025: Press Release

Jagsonpal Pharmaceuticals has announced a board meeting on the financial results for the quarter and half-year. FY25 revenue grew 28.8% to ₹268.7 Cr, with operating EBITDA jumping 59.1% to ₹57.9 Cr and margins expanding 410 bps to 21.5%. Business PAT rose 66.7% to ₹37.5 Cr. Growth was led by the Yash Pharma acquisition, enhancing dermatology and pediatrics segments. The Indocap® brand crossed ₹50 Cr, reinforcing leadership in pain management. A strong cash balance of ₹145.6 Cr supports further organic and inorganic expansion.